Tech Session I: Nanomedicine and Nanoscale Delivery (Focus: Immuno)
Subcutaneous administration of antibody-drug-conjugates
Tuesday, July 15, 2025
10:04 AM – 10:29 AM EDT
Introduction: Antibody-drug conjugates (ADCs) represent a promising class of targeted therapies in oncology [1]. However, their traditional intravenous (IV) administration presents challenges, including systemic toxicity, patient discomfort, and frequent hospital visits [2]. To address these limitations, we have developed a novel chitosan-based subcutaneous (SC) polymer platform that enables controlled and sustained release of ADCs. This platform aims to improve patient compliance and reduce local and systemic toxicities associated with ADC therapies [3].
Learning Objectives:
At the completion of this activity, participants will know
Upon compreletion, participant will be able to compare SC formulation through PK readouts
Upon completion, participant will be able to assess the challenge of SC administration
Upon completion, participant will be able to conduct SC screening studies
